Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Endocrine 1

Conditions

Prostatic Neoplasms 6 Gastro-enteropancreatic neuroendocrine tumor 2 Urogenital Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Prostatic Diseases 1 Prostate Cancer Metastatic 1 Pheochromocytoma 1 Paraganglioma 1 Neuroendocrine Tumors 1 Metastatic Neuroendocrine Prostate Cancer 1 Metastatic Castration-resistant Prostate Cancer (mCRPC) 1 Metastatic Castration-Resistant Prostate Cancer 1 Metastatic Castration Resistant Prostate Cancer (mCRPC) 1 Lung Neoplasms 1 Digestive System Neoplasms 1 Breast Neoplasms 1 Advanced Gastroenteropancreatic Neuroendocrine Tumor 1

Interventions

lutetium Lu 177 dotatate 20 Magnetic Resonance Spectroscopy 10 pembrolizumab 9 Specimen Handling 7 Everolimus 7 cabozantinib 6 Nivolumab 6 lenvatinib 5 177Lu-octreotide, DOTA(0)-Tyr(3)- 5 surufatinib 4 amino-acid, glucose, and electrolyte solution 4 Capecitabine 4 olaparib 3 lanreotide 3 atezolizumab 3 Temozolomide 3 Octreotide 3 Lutetium-177 3 Ipilimumab 3 Injections 3 Fluorodeoxyglucose F18 3 Cyclophosphamide 3 gallium Ga 68 dotatate 2 fludarabine phosphate 2 fludarabine 2 avelumab 2 X-Rays 2 Radiotherapy 2 Phantoms, Imaging 2 PM 01183 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neuroendocrine Tumors × Lutetium × 1 year × Clear all

NCT06878664 2025-09-02

RIALTO

Grupo Espanol de Tumores Neuroendocrinos

Phase 3 Recruiting

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡